東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Pharmaceutical Lifecycles: Maximizin...

Graysmark, Charles C.

FindBook

Google Book

Amazon

博客來

Pharmaceutical Lifecycles: Maximizing Profits.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Pharmaceutical Lifecycles: Maximizing Profits./
作者:	Graysmark, Charles C.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2016,
面頁冊數:	46 p.
附註:	Source: Masters Abstracts International, Volume: 56-03.
Contained By:	Masters Abstracts International56-03(E).
標題:	Management. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10256582
ISBN:	9781369560107

Pharmaceutical Lifecycles: Maximizing Profits.
Graysmark, Charles C.

Pharmaceutical Lifecycles: Maximizing Profits. - Ann Arbor : ProQuest Dissertations & Theses, 2016 - 46 p.

Source: Masters Abstracts International, Volume: 56-03.

Thesis (M.B.A.)--The College of St. Scholastica, 2016.

This project examines why and how the lifecycle of a pharmaceutical drug differs from most other commercially manufactured and distributed products. It began with a review of literature that analyzed articles about traditional product lifecycles and the strategies that are used in each phase of those cycles. It next examined resources specific to pharmaceutical manufacturing and the factors that differentiate that industry from others. A major finding was that pharmaceuticals spend a considerable part of their total lifetime in the research and development phase, adding significantly to costs and undesirable impacts on the public. Based on the information that emerged from the literature, the project concludes by recommending strategies that, if implemented, would result in pharmaceutical companies protecting their investment, experiencing long-term profits, and better serving the public need.

ISBN: 9781369560107Subjects--Topical Terms:

516664
Management.

Pharmaceutical Lifecycles: Maximizing Profits.
LDR:01772nmm a2200289 4500 001 2121004
005 20170724102936.5
008 180830s2016 ||||||||||||||||| ||eng d
020 $a 9781369560107
035 $a (MiAaPQ)AAI10256582
035 $a AAI10256582
040 $a MiAaPQ $c MiAaPQ
100 1 $a Graysmark, Charles C. $3 3282992
245 1 0 $a Pharmaceutical Lifecycles: Maximizing Profits.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2016
300 $a 46 p.
500 $a Source: Masters Abstracts International, Volume: 56-03.
500 $a Adviser: Robert J. Hartl.
502 $a Thesis (M.B.A.)--The College of St. Scholastica, 2016.
520 $a This project examines why and how the lifecycle of a pharmaceutical drug differs from most other commercially manufactured and distributed products. It began with a review of literature that analyzed articles about traditional product lifecycles and the strategies that are used in each phase of those cycles. It next examined resources specific to pharmaceutical manufacturing and the factors that differentiate that industry from others. A major finding was that pharmaceuticals spend a considerable part of their total lifetime in the research and development phase, adding significantly to costs and undesirable impacts on the public. Based on the information that emerged from the literature, the project concludes by recommending strategies that, if implemented, would result in pharmaceutical companies protecting their investment, experiencing long-term profits, and better serving the public need.
590 $a School code: 0614.
650 4 $a Management. $3 516664
650 4 $a Pharmaceutical sciences. $3 3173021
690 $a 0454
690 $a 0572
710 2 $a The College of St. Scholastica. $b Management. $3 1671699
773 0 $t Masters Abstracts International $g 56-03(E).
790 $a 0614
791 $a M.B.A.
792 $a 2016
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10256582